BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 35988455)

  • 21. Combined systemic inflammation score (SIS) correlates with prognosis in patients with advanced pancreatic cancer receiving palliative chemotherapy.
    Markus M; Abendroth A; Noureddine R; Paul A; Breitenbuecher S; Virchow I; Schmid KW; Markus P; Schumacher B; Wiesweg M; Wendling J; Mende B; Siveke JT; Schuler M; Kasper S
    J Cancer Res Clin Oncol; 2021 Feb; 147(2):579-591. PubMed ID: 32839836
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Longitudinal analysis of cell-free mutated KRAS and CA 19-9 predicts survival following curative resection of pancreatic cancer.
    Hussung S; Akhoundova D; Hipp J; Follo M; Klar RFU; Philipp U; Scherer F; von Bubnoff N; Duyster J; Boerries M; Wittel U; Fritsch RM
    BMC Cancer; 2021 Jan; 21(1):49. PubMed ID: 33430810
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after curative intent surgical resection.
    Kim NH; Kim HJ
    Hepatobiliary Pancreat Dis Int; 2018 Oct; 17(5):450-455. PubMed ID: 30237091
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic value of postdiagnostic inflammation-based scores in short-term overall survival of advanced pancreatic ductal adenocarcinoma patients.
    Xiao Y; Xie Z; Shao Z; Chen W; Xie H; Qin G; Zhao N
    Medicine (Baltimore); 2017 Dec; 96(50):e9247. PubMed ID: 29390358
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Kras mutation correlating with circulating regulatory T cells predicts the prognosis of advanced pancreatic cancer patients.
    Cheng H; Luo G; Jin K; Fan Z; Huang Q; Gong Y; Xu J; Yu X; Liu C
    Cancer Med; 2020 Mar; 9(6):2153-2159. PubMed ID: 32017404
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preoperative maximum standardized uptake value and carbohydrate antigen 19-9 were independent predictors of pathological stages and overall survival in Chinese patients with pancreatic duct adenocarcinoma.
    Gu X; Zhou R; Li C; Liu R; Zhao Z; Gao Y; Xu Y
    BMC Cancer; 2019 May; 19(1):456. PubMed ID: 31092213
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of tumor grade on pancreatic cancer prognosis: validation of a novel TNMG staging system.
    Rochefort MM; Ankeny JS; Kadera BE; Donald GW; Isacoff W; Wainberg ZA; Hines OJ; Donahue TR; Reber HA; Tomlinson JS
    Ann Surg Oncol; 2013 Dec; 20(13):4322-9. PubMed ID: 23943022
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Next-Generation Radiogenomics Sequencing for Prediction of EGFR and KRAS Mutation Status in NSCLC Patients Using Multimodal Imaging and Machine Learning Algorithms.
    Shiri I; Maleki H; Hajianfar G; Abdollahi H; Ashrafinia S; Hatt M; Zaidi H; Oveisi M; Rahmim A
    Mol Imaging Biol; 2020 Aug; 22(4):1132-1148. PubMed ID: 32185618
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inflammatory and nutritional biomarkers as predictors of non-resectability and early recurrence in pancreatic and periampullary cancer.
    Gil M; Gomes A; Baptista M; Vale Martins R; Nunes V
    Minerva Surg; 2022 Apr; 77(2):130-138. PubMed ID: 34693672
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Frequencies and prognostic role of KRAS and BRAF mutations in patients with localized pancreatic and ampullary adenocarcinomas.
    Schultz NA; Roslind A; Christensen IJ; Horn T; Høgdall E; Pedersen LN; Kruhøffer M; Burcharth F; Wøjdemann M; Johansen JS
    Pancreas; 2012 Jul; 41(5):759-66. PubMed ID: 22699145
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comprehensive Analysis of Somatic Mutations in Driver Genes of Resected Pancreatic Ductal Adenocarcinoma Reveals KRAS G12D and Mutant TP53 Combination as an Independent Predictor of Clinical Outcome.
    Shoucair S; Habib JR; Pu N; Kinny-Köster B; van Ooston AF; Javed AA; Lafaro KJ; He J; Wolfgang CL; Yu J
    Ann Surg Oncol; 2022 Apr; 29(4):2720-2731. PubMed ID: 34792696
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic value of γ-glutamyltransferase-to-albumin ratio in patients with pancreatic ductal adenocarcinoma following radical surgery.
    Li S; Xu H; Wu C; Wang W; Jin W; Gao H; Li H; Zhang S; Xu J; Zhang W; Xu S; Li T; Ni Q; Yu X; Liu L
    Cancer Med; 2019 Feb; 8(2):572-584. PubMed ID: 30632317
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pancreatic cancer surgery in the new millennium: better prediction of outcome.
    Hartwig W; Hackert T; Hinz U; Gluth A; Bergmann F; Strobel O; Büchler MW; Werner J
    Ann Surg; 2011 Aug; 254(2):311-9. PubMed ID: 21606835
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A machine learning model for the prediction of survival and tumor subtype in pancreatic ductal adenocarcinoma from preoperative diffusion-weighted imaging.
    Kaissis G; Ziegelmayer S; Lohöfer F; Algül H; Eiber M; Weichert W; Schmid R; Friess H; Rummeny E; Ankerst D; Siveke J; Braren R
    Eur Radiol Exp; 2019 Oct; 3(1):41. PubMed ID: 31624935
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Validation and modification of the AJCC 8th TNM staging system for pancreatic ductal adenocarcinoma in a Chinese cohort: A nationwide pancreas data center analysis.
    Hu H; Qu C; Tang B; Liu W; Ma Y; Chen Y; Xie X; Zhuang Y; Gao H; Tian X; Yang Y
    Chin J Cancer Res; 2021 Aug; 33(4):457-469. PubMed ID: 34584371
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A new prognosis prediction model combining TNM stage with MAP2K4 and JNK in postoperative pancreatic cancer patients.
    Liu XD; Zhang ZW; Wu HW; Liang ZY
    Pathol Res Pract; 2021 Jan; 217():153313. PubMed ID: 33341545
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Derivation and External Validation of Machine Learning-Based Model for Detection of Pancreatic Cancer.
    Chen W; Zhou Y; Xie F; Butler RK; Jeon CY; Luong TQ; Zhou B; Lin YC; Lustigova E; Pisegna JR; Kim S; Wu BU
    Am J Gastroenterol; 2023 Jan; 118(1):157-167. PubMed ID: 36227806
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of the prognostic values of various inflammation based factors in patients with pancreatic cancer.
    Wang DS; Luo HY; Qiu MZ; Wang ZQ; Zhang DS; Wang FH; Li YH; Xu RH
    Med Oncol; 2012 Dec; 29(5):3092-100. PubMed ID: 22476808
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Systemic-immune-inflammation Index Independently Predicts Survival and Recurrence in Resectable Pancreatic Cancer and its Prognostic Value Depends on Bilirubin Levels: A Retrospective Multicenter Cohort Study.
    Aziz MH; Sideras K; Aziz NA; Mauff K; Haen R; Roos D; Saida L; Suker M; van der Harst E; Mieog JS; Bonsing BA; Klaver Y; Koerkamp BG; van Eijck CH
    Ann Surg; 2019 Jul; 270(1):139-146. PubMed ID: 29334554
    [TBL] [Abstract][Full Text] [Related]  

  • 40. International Validation of the Eighth Edition of the American Joint Committee on Cancer (AJCC) TNM Staging System in Patients With Resected Pancreatic Cancer.
    van Roessel S; Kasumova GG; Verheij J; Najarian RM; Maggino L; de Pastena M; Malleo G; Marchegiani G; Salvia R; Ng SC; de Geus SW; Lof S; Giovinazzo F; van Dam JL; Kent TS; Busch OR; van Eijck CH; Koerkamp BG; Abu Hilal M; Bassi C; Tseng JF; Besselink MG
    JAMA Surg; 2018 Dec; 153(12):e183617. PubMed ID: 30285076
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.